Last reviewed · How we verify

Pneumococcal 7-valent conjugate vaccine — Competitive Intelligence Brief

Pneumococcal 7-valent conjugate vaccine (Pneumococcal 7-valent conjugate vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Conjugate vaccine. Area: Immunology / Infectious Disease.

phase 3 Conjugate vaccine Streptococcus pneumoniae capsular polysaccharides (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Pneumococcal 7-valent conjugate vaccine (Pneumococcal 7-valent conjugate vaccine) — National Institute of Allergy and Infectious Diseases (NIAID). This vaccine stimulates the immune system to produce antibodies against 7 serotypes of Streptococcus pneumoniae by presenting pneumococcal polysaccharide antigens conjugated to a protein carrier.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pneumococcal 7-valent conjugate vaccine TARGET Pneumococcal 7-valent conjugate vaccine National Institute of Allergy and Infectious Diseases (NIAID) phase 3 Conjugate vaccine Streptococcus pneumoniae capsular polysaccharides (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F)
Prevnar 20 pneumococcal 20-valent conjugate vaccine (PCV20) Pfizer Inc. marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae capsular polysaccharides (20 serotypes) 2021-06-08
Meningococcal (vaccine) Meningococcal (vaccine) GlaxoSmithKline marketed Bacterial polysaccharide conjugate vaccine Neisseria meningitidis capsular polysaccharides and outer membrane proteins
MenACWY Vaccine menacwy-vaccine Pfizer marketed Conjugate vaccine Meningococcal antigens
MenC MenC Novartis Vaccines marketed Conjugate vaccine Capsular polysaccharide of Neisseria meningitidis serogroup C
Meningococcal A conjugate vaccine Meningococcal A conjugate vaccine PATH marketed Conjugate vaccine Neisseria meningitidis serogroup A polysaccharide capsule
MenACWY-CRM (Menveo) MenACWY-CRM (Menveo) GlaxoSmithKline marketed Conjugate vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Conjugate vaccine class)

  1. GlaxoSmithKline · 26 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 6 drugs in this class
  3. CanSino Biologics Inc. · 3 drugs in this class
  4. MCM Vaccines B.V. · 3 drugs in this class
  5. Beijing Minhai Biotechnology Co., Ltd · 3 drugs in this class
  6. Wyeth is now a wholly owned subsidiary of Pfizer · 2 drugs in this class
  7. PT Bio Farma · 2 drugs in this class
  8. LG Life Sciences · 2 drugs in this class
  9. Walvax Biotechnology Co., Ltd. · 2 drugs in this class
  10. Heinrich-Heine University, Duesseldorf · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pneumococcal 7-valent conjugate vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/pneumococcal-7-valent-conjugate-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: